CN110412281A - BEGAIN autoantibody detection reagent is preparing the purposes in screening lung cancer kit - Google Patents
BEGAIN autoantibody detection reagent is preparing the purposes in screening lung cancer kit Download PDFInfo
- Publication number
- CN110412281A CN110412281A CN201910572842.7A CN201910572842A CN110412281A CN 110412281 A CN110412281 A CN 110412281A CN 201910572842 A CN201910572842 A CN 201910572842A CN 110412281 A CN110412281 A CN 110412281A
- Authority
- CN
- China
- Prior art keywords
- reagent
- begain
- lung cancer
- autoantibody
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to external diagnosis reagent fields, and in particular to BEGAIN autoantibody detection reagent is preparing the purposes in screening lung cancer kit.Present invention firstly discovers that the autoantibody of BEGAIN albumen is significantly higher than healthy patients in Serum of Patients with Lung Cancer.The reagent that the present invention will test BEGAIN albumen autoantibody is used to prepare screening lung cancer kit, can be realized effective screening of lung cancer.
Description
Technical field
The present invention relates to external diagnosis reagent fields, and in particular to BEGAIN autoantibody detection reagent is in preparation lung cancer sieve
Look into the purposes in kit.
Background technique
Lung cancer is that one of most common malignant tumour, morbidity and mortality are in rise year by year trend in the world, at present
Disease incidence occupies first place in the world, and seriously threatens human health and life.
Lung cancer is a kind of disease for being good at concealment, often develops to advanced stage in disease and just shows clinical symptoms, 70~
80% patients with lung cancer has been middle and advanced stage when being diagnosed to be with Lung Cancer Symptoms, and cancer cell has been spread, and misses best healing
Opportunity, five year survival rate are low.For the patients with lung cancer of early stage, giving birth to for 5 years or more for patient is greatly improved by treating in time
Deposit rate and life quality.Therefore the early diagnosis and the effective screening of progress of lung cancer are most important.
The screening of lung cancer, referring to does not have the related indication crowd of lung cancer to carry out routine physical examination those, before there is symptom
Discovery lung cancer in time.If the lung cancer molecular marker inside blood plasma can be found, for prompting clinician's early stage to patient
Relevant remedy measures or decision are taken to have great importance.
Autoantibody refers to the antibody that body generates itself organ, cell or cell component.Currently, certain albumen from
Body antibody has become the marker of lung cancer, such as: p53, NY-ESO-1, CYFRA (Tang Z-M, Ling Z-G, Wang
C-M, Wu Y-B, Kong J-L (2017) Serum tumor-associated autoantibodies as diagnostic
Biomarkers for lung cancer:A systematic review and meta-analysis.PLoS ONE 12
(7): e0182117).
BEGAIN (Ensembl:ENSG00000183092) is rich in the guanylate kinase GAP-associated protein GAP with intracerebral
(brain-enriched guanylate kinase-associated protein), has with intracerebral neuronal signal transduction
It closes, for example studies have reported that it is related with the chronic ache after peripheral nerve injury.There is not been reported for its relationship with cancer, mesh
Preceding there are no the relevant reports of BEGAIN albumen autoantibody, also have no its prior art relevant to lung cancer.
Summary of the invention
The purpose of the present invention is to provide the detections of the lung cancer marker and the marker of a kind of new autoantibody class
Reagent is preparing the purposes in screening lung cancer kit.
Technical solution of the present invention includes:
The reagent of detection BEGAIN albumen autoantibody is preparing the purposes in screening lung cancer kit.
The reagent of purposes as the aforementioned, the detection BEGAIN albumen autoantibody is enzyme-linked immunosorbent assay reagent
Or linked immune analysis reagent.
The reagent of purposes as the aforementioned, the detection BEGAIN albumen autoantibody is western blot reagent.
Purposes as the aforementioned, the reagent of the detection BEGAIN albumen autoantibody are the examination of protein chip detection method
Agent.
Purposes as the aforementioned, the reagent of the detection BEGAIN albumen autoantibody are BEGAIN albumen in detection human serum
The reagent of autoantibody.
A kind of screening lung cancer kit, it includes the reagent for detecting BEGAIN albumen autoantibody.
Kit as the aforementioned, the reagent of the detection BEGAIN albumen autoantibody are enzyme-linked immunosorbent assay examination
Agent or ELISA reagent.
The reagent of kit as the aforementioned, the detection BEGAIN albumen autoantibody is western blot reagent.
Kit as the aforementioned, the reagent of the detection BEGAIN albumen autoantibody are the examination of protein chip detection method
Agent.
Kit as the aforementioned, the reagent of the detection BEGAIN albumen autoantibody are BEGAIN eggs in detection human serum
The reagent of white autoantibody.
The present invention provides a kind of new screening lung cancer markers and a kind of new screening lung cancer kit, can be realized lung
Effective screening of cancer；And patient can be injured very low using serum as test sample.The present invention has good application prospect.
Obviously, above content according to the present invention is not being departed from according to the ordinary technical knowledge and customary means of this field
Under the premise of the above-mentioned basic fundamental thought of the present invention, the modification, replacement or change of other diversified forms can also be made.
Above content of the invention is described in further detail again below by way of specific embodiment.But it should not be by this
The range for being interpreted as the above-mentioned theme of the present invention is only limitted to example below.All technologies realized based on above content of the present invention are equal
Belong to the scope of the present invention.
Hereinafter " BEGAIN autoantibody " refers to " BEGAIN albumen autoantibody ".
Detailed description of the invention
Fig. 1: patients with lung cancer (LC), lung's benign disease (DC), normal healthy controls (NC) serum slurry in BEGAIN autoantibody
Level comparison.
Fig. 2: patients with lung cancer (LC) and normal healthy controls (NC) ROC are analyzed.
Specific embodiment
The relationship of BEGAIN autoantibody and lung cancer in 1 blood plasma of embodiment
One, clinical data
Patients with lung cancer 30 are chosen, normal healthy controls 30, essential information is as follows:
| Essential information | Patients with lung cancer | Normal healthy controls |
| Number | 30 | 30 |
| Age | 58±10.5 | 42±8.9 |
| Masculinity proportion | 20 (66.7%) | 13 (46.7%) |
Two, testing principle
HuProtTMBEGAIN albumen is fixed on human protein's custom chip, after increase serum is incubated for, BEGAIN in serum
Autoantibody (including mainly IgG, IgM type antibody, there are also other types of antibody) can be in conjunction with up, and cleaning removal is not tied
The antibody and other oroteins of conjunction, then with anti-human IgM fluorescent marker secondary antibody (cy5 mark, present red) and anti-human igg fluorescence two
Anti- (cy3 label, green is presented) detection reads signal, the power and the affinity sum number of antibody of signal by Fluorescence Scanner
Amount is positively correlated.
Three, method
Reagent used in this part is as follows:
Specific step is as follows:
1) rewarming: chip is taken out from -80 DEG C of refrigerators, 4 DEG C of refrigerator rewarming half an hour is placed in, is subsequently placed in room temperature rewarming
15min；
2) close: the chip after rewarming fixes 14 blocks fences, and after fixing, envelope is added into each block
Liquid is closed, and is placed on side-sway shaking table, room temperature closes 3hr；
3) serum sample is incubated for: after the completion of closing, then confining liquid to the greatest extent is rapidly added preprepared serum and is incubated for
Liquid, every chip can be incubated for 14 serum samples, and the loading volume of each serum sample is 200 μ L, side-sway shaking table 20rpm, and 4 DEG C
It is incubated overnight (serum sample is firstly placed on 4 DEG C of chromatography cabinet freeze thawing, adds Incubating Solution with 1: 50 dilution proportion, obtains serum Incubating Solution)；
4) it cleans: chip and chip fence being taken out together, suck sample, is then rapidly added isometric PBST, such as
This circulation for several times, guarantees when removing chip fence no cross contamination between serum sample.After removing chip fence, chip is placed in
Added with the chip cleaning box of cleaning solution, horizontal shaker, room temperature 80rpm is cleaned 3 times, each 10min；
5) secondary antibody is incubated for: chip being transferred in the incubation box that joined 3mL secondary antibody Incubating Solution, side-sway shaking table 40rpm is kept away
Light, room temperature 1hr；
6) it cleans: chip being taken out into (upper surface for paying attention to touch or scratching chip), is placed in the core added with cleaning solution
Piece cleaning box, horizontal shaker, room temperature 80rpm are cleaned 3 times, each 10min.It is cleaned 2 times with ddH2O after the completion, each 10min；
7) dry；
8) it scans: being scanned using brilliant core LuxScan 10K micro-array chip scanner；
9) data are extracted: corresponding GAL file (having recorded albumen position in chip) is opened, by chip image and
The each array of GAL file is integrally aligned, and presses automatic aligning button, is extracted data and is saved.
Four, result
The Average expression level of BEGAIN autoantibody in Plasma of The Patients With Lung Cancer is that (fluorescence signal is relatively fixed by 70.5SNR
Measure ratio), the Average expression level of BEGAIN autoantibody is 47.5SNR in normal healthy controls blood plasma.Lung cancer group and normal healthy controls
Group (p < 0.05) compares statistically significant (Fig. 1).It is 96.6% that the ROC of lung cancer group and normal healthy controls, which analyzes result specificity,
Sensibility is 13.8% (Fig. 2), shows that BEGAIN autoantibody can specifically distinguish lung cancer and normal healthy controls.
It can be seen from the above result that the level difference of BEGAIN autoantibody is aobvious in patients with lung cancer and the serum of non-lung cancer patient
It writes, by the level of BEGAIN autoantibody in detection serum, can achieve the purpose that screening lung cancer.
The composition and its application method of the detection kit of the invention of embodiment 2
One, kit forms
Detection kit (14 person-portion):
Two, kit application method
With 1 Part III of embodiment --- " detection of BEGAIN autoantibody in serum ".
Kit of the invention can be by the level of BEGAIN autoantibody in detection serum, can be with screening crowd to be checked
Suffer from the risk of lung cancer: if BEGAIN autoantibody is high (for Healthy People), the risk for suffering from lung cancer is high, if
BEGAIN autoantibody is low, then the risk for suffering from lung cancer is low.It can be used for the auxiliary diagnosis of clinical lung cancer, take correlation for patient
Remedy measures or decision provide effective foundation, potential applicability in clinical practice is good.
Claims (10)
1. the reagent of detection BEGAIN albumen autoantibody is preparing the purposes in screening lung cancer kit.
2. purposes as described in claim 1, which is characterized in that the reagent of the detection BEGAIN albumen autoantibody is enzyme-linked
Immunosorbent adsorption test reagent or linked immune analysis reagent.
3. purposes as described in claim 1, which is characterized in that it is described detection BEGAIN albumen autoantibody reagent be
Western blot reagent.
4. purposes as described in claim 1, which is characterized in that the reagent of the detection BEGAIN albumen autoantibody is albumen
Chip detecting method reagent.
5. the purposes as described in Claims 1 to 4 is any, which is characterized in that the examination of the detection BEGAIN albumen autoantibody
Agent is the reagent for detecting BEGAIN albumen autoantibody in human serum.
6. a kind of screening lung cancer kit, which is characterized in that it includes the reagent for detecting BEGAIN albumen autoantibody.
7. kit as claimed in claim 6, which is characterized in that the reagent of the detection BEGAIN albumen autoantibody is enzyme
Linked immunosorbent adsorption test reagent or ELISA reagent.
8. kit as claimed in claim 6, which is characterized in that it is described detection BEGAIN albumen autoantibody reagent be
Western blot reagent.
9. kit as claimed in claim 6, which is characterized in that the reagent of the detection BEGAIN albumen autoantibody is egg
White chip detecting method reagent.
10. the kit as described in claim 5~9 is any, which is characterized in that the detection BEGAIN albumen autoantibody
Reagent is the reagent for detecting BEGAIN albumen autoantibody in human serum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910572842.7A CN110412281B (en) | 2019-06-26 | 2019-06-26 | Application of BEGAIN autoantibody detection reagent in preparation of lung cancer screening kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910572842.7A CN110412281B (en) | 2019-06-26 | 2019-06-26 | Application of BEGAIN autoantibody detection reagent in preparation of lung cancer screening kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110412281A true CN110412281A (en) | 2019-11-05 |
| CN110412281B CN110412281B (en) | 2022-09-09 |
Family
ID=68358395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910572842.7A Active CN110412281B (en) | 2019-06-26 | 2019-06-26 | Application of BEGAIN autoantibody detection reagent in preparation of lung cancer screening kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110412281B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112415199A (en) * | 2020-11-20 | 2021-02-26 | 四川大学华西医院 | Application of CETP detection reagent in preparation of lung cancer screening kit |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090053831A1 (en) * | 2007-05-01 | 2009-02-26 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
| US20110236903A1 (en) * | 2008-12-04 | 2011-09-29 | Mcclelland Michael | Materials and methods for determining diagnosis and prognosis of prostate cancer |
| WO2014193999A2 (en) * | 2013-05-28 | 2014-12-04 | Caris Science, Inc. | Biomarker methods and compositions |
| US20150152474A1 (en) * | 2012-03-09 | 2015-06-04 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarker compositions and methods |
| US20160319361A1 (en) * | 2013-08-28 | 2016-11-03 | Caris Life Sciences Switzerland Holdings Gmbh | Oligonucleotide probes and uses thereof |
| CN106232833A (en) * | 2014-01-30 | 2016-12-14 | 加利福尼亚大学董事会 | The haplotyping that methylates (MONOD) for non-invasive diagnostic |
| CN106973568A (en) * | 2014-10-08 | 2017-07-21 | 诺华股份有限公司 | Prediction is for biological marker of therapeutic response of Chimeric antigen receptor therapy and application thereof |
| US20180171337A1 (en) * | 2015-06-29 | 2018-06-21 | Caris Science, Inc. | Therapeutic oligonucleotides |
| US20190049435A1 (en) * | 2015-04-24 | 2019-02-14 | Cornell University | Methods and reagents for determination and treatment of organotropic metastasis |
-
2019
- 2019-06-26 CN CN201910572842.7A patent/CN110412281B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090053831A1 (en) * | 2007-05-01 | 2009-02-26 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
| US20110236903A1 (en) * | 2008-12-04 | 2011-09-29 | Mcclelland Michael | Materials and methods for determining diagnosis and prognosis of prostate cancer |
| US20150152474A1 (en) * | 2012-03-09 | 2015-06-04 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarker compositions and methods |
| WO2014193999A2 (en) * | 2013-05-28 | 2014-12-04 | Caris Science, Inc. | Biomarker methods and compositions |
| US20160319361A1 (en) * | 2013-08-28 | 2016-11-03 | Caris Life Sciences Switzerland Holdings Gmbh | Oligonucleotide probes and uses thereof |
| CN106232833A (en) * | 2014-01-30 | 2016-12-14 | 加利福尼亚大学董事会 | The haplotyping that methylates (MONOD) for non-invasive diagnostic |
| CN106973568A (en) * | 2014-10-08 | 2017-07-21 | 诺华股份有限公司 | Prediction is for biological marker of therapeutic response of Chimeric antigen receptor therapy and application thereof |
| US20190049435A1 (en) * | 2015-04-24 | 2019-02-14 | Cornell University | Methods and reagents for determination and treatment of organotropic metastasis |
| US20180171337A1 (en) * | 2015-06-29 | 2018-06-21 | Caris Science, Inc. | Therapeutic oligonucleotides |
Non-Patent Citations (2)
| Title |
|---|
| CDI-LAB.COM: "HuProt v3 block 12", 《HTTPS://COLLECTION.CDI-LAB.COM/PUBLIC/GAL/3/12?PAGE=11》 * |
| 裴露: "基于SEREX技术及Oncomine数据库对肺癌相关抗原的筛选与鉴定", 《中国优秀博硕士学位论文全文数据库(硕士)医药卫生科技辑》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112415199A (en) * | 2020-11-20 | 2021-02-26 | 四川大学华西医院 | Application of CETP detection reagent in preparation of lung cancer screening kit |
| CN112415199B (en) * | 2020-11-20 | 2023-09-08 | 四川大学华西医院 | Application of CETP detection reagent in preparation of lung cancer screening kit |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110412281B (en) | 2022-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110108879A (en) | ERP27 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110108877A (en) | FAM172A autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110412274A (en) | C6ORF106 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110412276A (en) | PDE9A autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110108880A (en) | FEZ1 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110456064A (en) | SARS2 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110412281A (en) | BEGAIN autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110456083A (en) | PRKCZ autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110456067A (en) | EHD2 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110412279A (en) | KLC3 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110412298A (en) | FCRL4 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110456068A (en) | XIRP1 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110412299A (en) | HECTD3 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110456061A (en) | RUNDC3A autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110412270A (en) | SSNA1 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110412273A (en) | CAAP1 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110412272A (en) | ALKBH3 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110412271A (en) | NCAM1 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110456070A (en) | HACE1 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110488019A (en) | REPS1 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110456065A (en) | CCDC130 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110412278A (en) | SLC1A3 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110456080A (en) | C14orf37 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110108878A (en) | EIF2S1 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110456066A (en) | DBNL autoantibody detection reagent is preparing the purposes in screening lung cancer kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |